Anemia in chronic heart failure

Congestive Heart Failure

Volumn 15, Issue 2, 2009, Pages 87-92

  Drakos, Stavros G ^a   Anastasiou nana, Maria I ^a   Malliaras, Konstantinos G ^a   Nanas, John N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC DISEASE; CLINICAL TRIAL; DIASTOLIC DYSFUNCTION; DRUG HALF LIFE; DRUG MECHANISM; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT;

ANEMIA; ANEMIA, IRON-DEFICIENCY; ANIMALS; CAUSALITY; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIASTOLE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE; HEMATINICS; HUMANS; IRON COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 65449115681     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00049.x     Document Type: Review

References (50)

1. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
2. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure. J Am Coll Cardiol. 2003;41:1933-1939.
3. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
4. Felker GM, Shaw LK, Stough WG, et al. Anemia in patients with heart failure and preserved systolic function. Am Heart J. 2006;151:457-462.
5. O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113:986-994.
6. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Circulation. 2003;107:223-225.
7. Tang YD, Katz SD. Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454-2461.
8. Mitchell JE. Emerging role of anemia in heart failure. Am J Cardiol. 2007;99:15D-20D.
9. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
10. Anand I, McMurray JJV, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154.
11. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
12. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85:51-66.
13. Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol. 1999;70:7-12.
14. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485-2489.
15. McCullough PA, Lepor NE. Anemia: A modifiable risk factor for heart disease. Introduction. Rev Cardiovasc Med. 2005;6:S1-S3.
16. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
17. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4:681-686.
18. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J. 2007;28:166-171.
19. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226-229.
20. Rauchaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-3067.
21. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17:39-43.
22. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
23. Iversen PO, Woldbaek PR, Tonnessen T, et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol. 2002;282:R166-R172.
24. Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100:2310-2314.
25. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45:391-399.
26. Van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743-1747.
27. Anand IS. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med. 2005;6:S13-S21.
28. Olivetti G, Lagrasta C, Quaini F, et al. Capillary growth in anemia induced ventricular wall remodeling in the rat heart. Circ Res. 1989;65:1182-1192.
29. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
30. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
31. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-2189.
32. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
33. Berry C, Norrie J, Hogg K, et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J. 2006;151:1313-1321.
34. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381-388.
35. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al. Rationale and design of the IRON-HF study: A randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail. 2007;13:14-17.
36. Van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-133.
37. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
38. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406-1412.
39. Westenbrink BD, Lipsic E, Van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018-2027.
40. Asaumi Y, Kagaya Y, Takeda M, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation. 2007;115:2022-2032.
41. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
42. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
43. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096-1115.
44. Comin-Colet J, Ruiz-Ruiz V, Ortega A, et al. Influence on NT-proBNP levels and hospitalization of correction of mild anemia with intravenous iron and erythropoietin in patients with severe chronic heart failure. Eur J Heart Fail. 2006;5:122 [Abstract].
45. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49:753-762.
46. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208-2216.
47. Abraham WT, Klapholz M, Anand I, et al. The effect of darbepoetin alfa treatment on clinical outcomes in anemic patients with symptomatic heart failure: A preplanned pooled analysis of two randomized, double-blind, placebo controlled trials. Eur J Heart Fail. 2006;5:121 [Abstract].
48. Ghali JK, Anand I, Abraham WT, et al. Randomized, double-blind, placebo controlled trial to assess the impact of darbepoetin alfa treatment on exercise tolerance in anemic patients with symptomatic heart failure: results from STAMINA-HeFT. Eur J Heart Fail. 2006;5:122 [Abstract].
49. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-1227.
50. Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657-1665.